This website uses cookies primarily for visitor analytics. Certain pages will ask you to fill in contact details to receive additional information. On these pages you have the option of having the site log your details for future visits. Indicating you want the site to remember your details will place a cookie on your device. To view our full cookie policy, please click here. You can also view it at any time by going to our Contact Us page.

Revolutionising the treatment of respiratory disease

04 December 2023

Medical device developer Wideblue has worked with client TidalSense over the past 10 years, to produce the world’s first handheld capnometer targeting the management of chronic respiratory conditions.

Traditionally, capnometers have been used in hospitals as an essential tool during anaesthesia and intensive care, to track respiratory failure. Evidence has suggested that capnometry could be used to identify airway obstruction associated with asthma and chronic obstructive pulmonary disease (COPD).

These diseases affect almost 10 percent of the world’s population, with COPD now listed as the third leading cause of death worldwide. This is predominantly driven by smoking and air pollution. Yet, advances in respiratory care management have not kept pace. Late and inaccurate diagnosis of these conditions results in billions of pounds in healthcare costs, through exacerbations leading to hospitalisations, many of which are preventable. 
The challenge for Wideblue was to support TidalSense in designing an easy-to-use handheld device which could collect breath waveform data for use in a GP’s surgery or the patient’s home, and securely transmit the data to a remote server. 

Read the full article in DPA's December issue

Contact Details and Archive...

Print this page | E-mail this page